Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 6

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
-  
     -  
     -  
     -  
     -  
     -  
     (1,595,959) 
     (1,595,959)
  
    Balance as of September 30,2025 
     17.488  
    $-  
     -  
    $-  
     786,902  
    $77  
    $107,467,603  
    $-  
    $(107,296,300) 
    $171,380 

The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.

4

ENDRA Life Sciences Inc.

Condensed Consolidated Statements
of Cash Flows

(Unaudited)

    Nine Months  
    Nine Months 

    Ended  
    Ended 

    September 30,  
    September 30, 

    2025  
    2024 
  
    Cash Flows from Operating Activities 

    Net loss 
    $(3,858,201) 
    $(7,358,943)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation and amortization 
     33,928  
     35,489 
  
    Fixed assets write off 
     -  
     8,808 
  
    Inventory reserve 
     -  
     4,687 
  
    Stock compensation expense 
     316,531  
     467,240 
  
    Amortization of right of use assets 
     83,834  
     124,320 
  
    Warrant expense 
        
     7,323,685 
  
    Changes in fair value of warrant liability 
     (203,400) 
     (3,341,829)
  
    Gain or Loss on settlement of warrant exercise 
        
     (3,071,252)
  
    Changes in operating assets and liabilities: 

    (Increase) Decrease in prepaid expenses 
     (50,488) 
     219,553 
  
    Increase in inventory 
     -  
     (93,745)
  
    (Increase) Decrease in accounts payable and accrued liabilities 
     163,224  
     (74,098)
  
    Decrease in lease liability